Sun Li, Zhang Hongwei, Wu Kaichun
Xijing Hospital of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Gastrointest Tumors. 2014 Jun;1(2):105-13. doi: 10.1159/000362907. Epub 2014 May 9.
Esophageal cancer (EC) is the eighth most common cancer worldwide. A worldwide-established consensus on therapeutic pathways for EC is still missing. Debate exists on whether neoadjuvant and adjuvant treatment regimens improve the prognosis and which surgical approach reaches objective benefits.
This article discusses the appropriate option of the current different curative treatments in patients with EC, including surgical treatment and adjuvant therapy.
To maximize survival and quality of life and also decrease postoperative complications, the present recommended therapeutic management of EC should be individualized multidisciplinary team approaches according to patients' staging and physiologic reserve.
The aim of this article is to provide a decision support and also a discussion based on clinical therapeutic strategy in order to characterize the beneficial approach which reaches an optimal balance between radical resection, postoperative outcome and long-term survival of EC.
食管癌(EC)是全球第八大常见癌症。目前在全球范围内尚未就食管癌的治疗途径达成共识。关于新辅助和辅助治疗方案是否能改善预后以及哪种手术方法能实现客观益处存在争议。
本文讨论了目前食管癌患者不同根治性治疗的合适选择,包括手术治疗和辅助治疗。
为了使生存率和生活质量最大化并减少术后并发症,目前推荐的食管癌治疗管理应根据患者的分期和生理储备采用个体化多学科团队方法。
本文旨在提供决策支持,并基于临床治疗策略进行讨论,以确定在食管癌的根治性切除、术后结果和长期生存之间达到最佳平衡的有益方法。